ArticleAvicenna journal of phytomedicine
Green tea polyphenols, epicatechin gallate and epigallocatechin gallate, alleviated aberrant metabolic changes caused by olanzapine in rats.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Olanzapine, a well-known antipsychotic drug, causes considerable weight gain and metabolic abnormalities in patients. Green tea ( Materials and Methods: We used fourteen groups of rats and subjected them to intraperitoneal injections once a day for eleven days: 1: Control. 2: Olanzapine (5 mg/kg/day). 3, 4, and 5: Olanzapine + EGCG (10, 20, and 40 mg/kg/day, respectively). 6, 7, and 8: EGCG (10, 20, and 40 mg/kg/day, respectively). 9, 10, and 11: Olanzapine + ECG (10, 20, and 40 mg/kg/day, respectively). 12, 13, and 14: ECG (10, 20, and 40 mg/kg/day). The body weights were recorded every three days and food consumption was evaluated every day. At the end of the study, lipid profile, systolic blood pressure (SBP), leptin and fasting blood sugar (FBS) levels, and locomotor activity were assessed. Results: Olanzapine considerably increased weight, food intake, triglycerides, low-density lipoprotein (LDL), cholesterol, SBP, leptin, and FBS, and decreased high-density lipoprotein (HDL), and locomotor activity. Co-administration of ECG or EGCG at different doses significantly suppressed olanzapine-induced weight gain, and elevated plasma lipids, SBP, leptin, and FBS levels. Both compounds also considerably increased locomotor activity and HDL levels. Conclusion: These findings suggest that ECG and EGCG could be promising adjunct therapies to counteract the metabolic side effects of olanzapine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.